Drug Designing: Open Access
Open Access

Comparative study of sitagliptin analysis on halogenated stationary phases in pharmaceutical formulation

International Conference and Expo on Drug Discovery & Designing

August 11-13, 2015 Frankfurt, Germany

Hebatallah A Wagdy1 and Hassan Y Aboul-Enein2

Posters-Accepted Abstracts: Drug Des

Abstract :

Sitagliptin [(2R)-1-(2,4,5-trifluorophenyl)-4-oxo-4-[3- (trifluoromethyl)-5,6 dihydro [1,2,4] triazolo [4, 3-a] pyrazin-7(8H)- yl]
butan-2-amine] is an antidiabetic drug, it corresponds the dipeptidyl peptidase-4 (DPP-4) inhibitor. Although it was developed
since 2006, only few methods were reported in literature for its analysis. None one of these methods have reported its analysis on
the newly developed halogenated stationary phases namely; pentabromobenzyl (PBr) and pentafluorophenyl (PFP) columns. This
investigation illustrates a comparison between the separation as well as the mechanism(s) involved in the separation of sitagliptine on
PBr and PFP columns which include interactive forces such as hydrogen bonding, pi-pi-stackking and dispersion force interaction. In
this method, standard solutions were prepared by dissolving the analyte in methanol and mobile phase and so is the pharmaceutical
tablet formulation. The HPLC conditions used were: a mobile phase composed of phosphate buffer (pHâ�?3.5): ACN (60:40v/v), the
flow rate was 1 ml/min, the detection wavelength was 260 nm. The pKa of sitagliptin was calculated using ACD/Labs software® was
7.19. The results showed difference in analysis time and solvent consumption between the 2 columns used in this study. Furthermore,
this study led to better understanding of the mechanism of action involved in these newly developed halogenated stationary phase
regarding the studied analyte and mobile phase/column parameters.